InvestorQ : InvestorQ-Ask,Answer & Share All About Finance!
Chandralekha Desai made post

What is the latest status of Bharat Biotech’s COVAXINE human trials for COVID-19?

Answer
user profile image
Mitali Bhutta answered.
2 weeks ago


Bharat Biotech’s COVAXINE as an immunity builder for the Coronavirus has already commenced during the last week. Vaccines are being administered to participants at AIIMS, Patna and PGIMS at Rohtak in Haryana. COVAXINE initiated Phase-1 clinical trials across India on 15 July 2020 in a randomised, double-blind, placebo-controlled environment.

AIIMS Patna was the first to start trials and has so far vaccinated 9 people with a smaller dose to check for safety. Based on initial results, the sample size will be expanded. Initial results have shown that there were no adverse reactions. The COVAXINE has been jointly developed by Bharat Biotech and National Institute of Virology, part of ICMR.

The Phase 1 and Phase 2 trials will be completed in a period of 15 months. It may be recollected that COVAXINE is the first indigenous vaccine to receive the DCGI approval for human trials. Zydus Cadila has also received approval for DCGI approval for trials. Of course, the ICMR request to launch the vaccine by August 15, does look a tad ambitious.